Schizophrenia has no blood test—diagnosis waits on months of lived signs
Hallucinations, delusions, disorganized thought or behavior, and flat or mismatched emotion can mark schizophrenia, usually emerging in young adulthood. There is no objective diagnostic assay. DSM-5 asks for at least six months of described symptoms; ICD-11 asks for one month, based on behavior, history, and reports from people who know the person.
Lifetime prevalence sits about 0.3% to 0.7%. Estimates include 1.1 million new cases in 2017 and 24 million people living with the condition in 2022. Males are affected more often and typically earlier. Causes appear mixed: common and rare genetic variants plus environmental factors such as urban upbringing, childhood adversity, adolescent cannabis use, infections, parental age, and poor prenatal nutrition. About half of those diagnosed improve markedly long-term without further relapse, a small share recovering fully; the other half live with lifelong impairment. Social fallout—unemployment, poverty, homelessness, exploitation—is common. Suicide risk is about 5% overall; physical illness shortens average life expectancy by 20 to 28 years. Roughly 17,000 deaths were linked to schizophrenia in 2015.
Symptoms group as positive, negative, and cognitive. Positive psychotic features—delusions, hallucinations, disorganized speech or behavior, inappropriate affect—overlap other psychoses and can be transient, complicating early labeling of a first-episode psychosis. Hallucinations occur at some point in about 80% of people with schizophrenia, most often voices, sometimes other senses; multisensory hallucinations run at twice the rate of single-sense ones and often match delusional themes. Passivity phenomena such as thought broadcasting appear. Culture shapes hallucination content. Negative symptoms include blunted affect, alogia, anhedonia, asociality, and avolition—often split into apathy versus diminished expression—and respond less well to medication, especially when primary rather than secondary to drugs or isolation. Scales such as CAINS and BNSS track these domains.
Cognitive deficits affect an estimated 70%, often years before frank illness, spanning verbal memory, attention, processing speed, and social cognition such as reading facial emotion; they predict function better than core symptom lists and rarely yield to antipsychotics alone, though cognitive remediation can help. Onset peaks in males’ early-to-mid twenties and females’ late twenties, with early-onset before 17 and childhood forms before 13; late-onset after 40 and very-late-onset after 60 show different sex ratios and dose needs. Up to 75% pass through a prodrome lasting months to five years. Treatment centers on antipsychotics such as olanzapine and risperidone plus counseling, job training, and rehabilitation; up to a third need clozapine after nonresponse. Short involuntary hospital stays may follow judged risk of harm; long stays are rarer where community supports exist.
Source: Schizophrenia
